CD33-targeted GSPT1 DAC

CD33-targeted GSPT1 DAC refers to a class of degrader-antibody conjugates (DACs) designed to treat myeloid malignancies by combining the precision of a CD33-targeting monoclonal antibody with the potent cell-killing mechanism of a GSPT1 (G1 to S phase transition 1) protein degrader. CD33 is a cell-surface antigen highly expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells, while GSPT1 is an essential translation termination factor. Upon binding to CD33 and internalization, the conjugate releases its payload, which induces the proteasomal degradation of GSPT1, leading to rapid apoptosis. This therapeutic architecture, exemplified by the clinical-stage asset ORM-6151 (developed by Orum Therapeutics and acquired by Bristol Myers Squibb), aims to provide a superior therapeutic index compared to traditional antibody-drug conjugates (ADCs) or systemic protein degraders by selectively targeting leukemic cells while minimizing off-target toxicity to healthy tissues.

Other names

anti-CD33 GSPT1 DACanti-CD-33 GSPT1 DACanti-CD 33 GSPT1 DACCD33-GSPT1 degrader antibody conjugateCD-33-GSPT1 degrader antibody conjugateCD 33-GSPT1 degrader antibody conjugate